Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKYO vs ARGX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARGX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

ARGX Overall Winner 6-Pillar Tally: OKYO 0 – 5 ARGX (1 Tie) Matrix Metrics: OKYO 0 – 10 ARGX

As of Nov 20, 2026, argenx SE (ARGX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKYO carries a Unified Composite Score of 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin), whereas ARGX carries 49.6/100 (HOLD) at $925.70 (27.8x Forward P/E, 31.9% operating margin).

  • Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile ARGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKYO vs ARGX
OKYO NASDAQ
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38
ARGX NASDAQ Head-to-Head Winner
argenx SE American Depositary Shares
Biological Products, (No Diagnostic Substances)
$925.70
-1.73% 1D
Market Cap $59.3B
TTM Revenue $5.92B
Forward P/E 27.8x
Beta / 30D Vol 0.56β · 31% Vol
Unified Composite Score
49.6 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.4 · SMA20: $926.20 · SMA50: $917.81

6-Pillar Scorecard Institutional Category Breakdown (OKYO 0 – 5 ARGX)

Columns: Metric · OKYO · ARGX
1. Valuation Multiples ARGX
Forward P/E N/M 27.8x
Trailing P/E N/M 32.6x
PEG Ratio N/M 1.28x
EV / Revenue N/M 10.0x
2. Growth & Scale ARGX
Revenue Growth (YoY) +0.0% +52.1%
Earnings Growth (YoY) +0.0% +50.6%
TTM Revenue (USD) N/A $5.92B
Market Cap $62.7M $59.3B
3. Profitability & Quality ARGX
Gross Margin N/A 59.8%
Operating Margin 0.0% 31.9%
Net Profit Margin 0.0% 31.7%
Return on Equity (ROE) -263.8% 23.6%
4. Balance Sheet & Cash Flow ARGX
Cash Generation (TTM) N/A $1.90B EBITDA
Cash Flow Margin N/A 32.1% EBITDA Mgn
Net Cash / Leverage $0.23 Book/Sh · -263.8% ROE $5.38 Book/Sh · 23.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 32.8% (33rd %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ARGX
OpEx & R&D Intensity N/A 27.9% of Rev ($1.65B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKYO (0) vs ARGX (10)
Institutional Metric OKYO ARGX Criterion Row Edge
Market Capitalization
Scale
$62.7M $59.3B Larger Scale ARGX
Trailing P/E Ratio
Valuation
N/M 32.6x Lower Multiple ARGX
Forward P/E Ratio
Valuation
N/M 27.8x Lower Multiple ARGX
Revenue Growth (YoY)
Growth
+0.0% +52.1% Higher Growth ARGX
Operating Margin (TTM)
Profitability
0.0% 31.9% Higher Margin ARGX
Net Profit Margin
Profitability
0.0% 31.7% Higher Margin ARGX
Return on Equity (ROE)
Capital Efficiency
-263.8% 23.6% Higher ROE ARGX
52-Week Range Position
Momentum
3% ($1–$3) 64% ($662–$1,073) Stronger Trend ARGX
Beta / 30D Volatility
Risk Regime
1.05β · 76% Vol 0.56β · 31% Vol Lower Realized Risk ARGX
Unified Institutional Score
Composite Signal
42.8 / 100 (HOLD) 49.6 / 100 (HOLD) Higher Composite ARGX
Trailing 12M Revenue (USD)
Operating Scale
N/A $5.92B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 59.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.28x PEG · 10.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.23 Book/Sh · -263.8% ROE) $1.90B EBITDA ($5.38 Book/Sh · 23.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARGX +32.91 pp
OKYO: -27.21% · ARGX: +5.7%
3M Horizon ARGX +20.22 pp
OKYO: -28.67% · ARGX: -8.45%
6M Horizon ARGX +49.15 pp
OKYO: -34.36% · ARGX: +14.79%
1Y Horizon ARGX +48.24 pp
OKYO: -47.03% · ARGX: +1.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKYO vs ARGX. Trailing 12-month operating profitability (OKYO 0.0% vs ARGX 31.9%) and valuation multiples (OKYO N/M vs ARGX 27.8x Forward P/E) are benchmarked directly in Pillar 4 below.

OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M
ARGX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.92B
Gross Margin59.8%
Op. Margin31.9%
ROE / Fwd P/E23.6% · 27.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARGX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 32.8%
IV Percentile 33rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARGX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $59.3B market capitalization and 31.9% operating margin.
OpEx & R&D Reinvestment 27.9% of Rev ($1.65B)
90D Engineering Disclosures 0 Published

Investor FAQ OKYO vs ARGX Key Questions & Quantitative Answers

As of Nov 20, 2026, argenx SE (ARGX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKYO carries a Unified Composite Score of 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin), whereas ARGX carries 49.6/100 (HOLD) at $925.70 (27.8x Forward P/E, 31.9% operating margin). Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile ARGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARGX leads the Growth & Scale pillar: OKYO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARGX at +52.1% YoY revenue growth and +50.6% YoY earnings growth on $5.92B TTM revenue (59.8% gross margin, 31.9% operating margin). On trailing 12-month operating scale, OKYO generates N/A in USD-normalized revenue versus $5.92B for ARGX. In operating R&D and SG&A reinvestment, OKYO deploys N/A (0 90-day corporate R&D disclosures) versus 27.9% of Rev ($1.65B) (0 disclosures) for ARGX.

ARGX screens cheaper on headline valuation multiples. OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ARGX trades at 27.8x Forward P/E, 32.6x Trailing P/E, 1.28x PEG, and 10.0x EV/Revenue (32.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKYO (-263.8% ROE) versus ARGX (23.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk). By comparison, ARGX carries 32.8% implied volatility (33rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.56β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.